Eris Lifesciences Limited (BOM:540596)
1,398.15
+54.56 (4.06%)
At close: May 29, 2026
Eris Lifesciences Revenue
In the fiscal year ending March 31, 2026, Eris Lifesciences had annual revenue of 31.15B INR with 8.18% growth. Eris Lifesciences had revenue of 7.52B in the quarter ending March 31, 2026, with 7.07% growth.
Revenue
31.15B
Revenue Growth
+8.18%
P/S Ratio
6.22
Revenue / Employee
9.29M
Employees
3,354
Market Cap
193.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 31.15B | 2.36B | 8.18% |
| Mar 31, 2025 | 28.79B | 8.88B | 44.59% |
| Mar 31, 2024 | 19.91B | 3.29B | 19.83% |
| Mar 31, 2023 | 16.62B | 3.36B | 25.31% |
| Mar 31, 2022 | 13.26B | 1.34B | 11.20% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| Sanofi India | 17.74B |
Eris Lifesciences News
- 12 days ago - Eris Lifesciences Transcript: Q4 25/26 - Transcripts
- 12 days ago - Eris Lifesciences Slides: Q4 2026 - Filings
- 12 days ago - Eris Lifesciences Quarterly report: Q4 2026 - Filings
- 12 days ago - Top gainers today: eris lifesciences at ₹1,458.20 up 9.13%, Tata communications at ₹1,775.60 up 7.83%, balaji amines at ₹1,833.30 up 7.29% - Business Upturn
- 5 weeks ago - Eris Lifesciences faces procedural non-compliance at Swiss Parenterals units - Business Upturn
- 2 months ago - Eris Lifesciences completes acquisition of Velbiom Probiotics business - Business Upturn
- 2 months ago - Eris Lifesciences partners with Natco Pharma for semaglutide launch in India - Business Upturn
- 3 months ago - Eris Lifesciences partners with Natco Pharma to launch Semaglutide in India - Business Upturn